Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1261 to 1275 of 1877 results for do not dos

  1. Healthy workplaces: improving employee mental and physical health and wellbeing (QS147)

    This quality standard covers the health and wellbeing of all employees, including their mental health. It describes high-quality care in priority areas for improvement. It does not cover managing long-term sickness absence.

  2. Transition between inpatient mental health settings and community or care home settings (QS159)

    This quality standard covers transitions for children, young people and adults between mental health hospitals and their own homes, care homes or other community settings. It includes the period before, during and after a person is admitted to, and discharged from, a mental health hospital. It describes high-quality care in priority areas for improvement.

  3. Guide to the technology appraisal and highly specialised technologies appeal process (pre June 2023) (PMG18)

    This document concerns the appeal process for the technology appraisal and highly specialised technologies programmes and provides an overview for organisations wishing to lodge an appeal

  4. Spectra Optia for automatic red blood cell exchange in people with sickle cell disease (HTG405)

    Evidence-based recommendations on Spectra Optia for automated red blood cell exchange in people with sickle cell disease.

  5. Factors predicting outcomes for people with high-grade transformation of follicular lymphoma:- In people with high-grade transformation of follicular lymphoma, which biological and clinical factors predict good outcomes with immunochemotherapy alone?

    clinical event, outcomes have improved. It is unclear which people are likely to do well with conventional treatment (such as R-CHOP)...

  6. The Insides System for managing intestinal failure (MIB286)

    NICE has developed a medtech innovation briefing (MIB) on The Insides System for managing intestinal failure .

  7. MiniMed 640G system with SmartGuard for managing blood glucose levels in people with type 1 diabetes (MIB51)

    NICE has developed a medtech innovation briefing (MIB) on MiniMed 640G system with SmartGuard for managing blood glucose levels in people with type 1 diabetes

  8. What is the efficacy and safety of remdesivir for people who have been vaccinated against COVID-19?

    (Population, Intervention, Comparator, Outcomes) P: people with COVID-19 who do not need supplemental oxygen and are within 7 days of...

  9. Risk assessment:- What is the accuracy of individual risk assessment tools in predicting the risk of venousthromboembolism (VTE) and risk of bleeding in people admitted to hospital?

    means that the national tool identifies too many people or the other tools do not identify enough. The potential impact of giving...

  10. What is the effectiveness of awake body positioning in improving outcomes for people in hospital with COVID-19 who are not intubated and have higher oxygen needs?

    mean duration of body positioning• people on general wards, and those with do-not-intubate goals of care• supplemental oxygen type•...

  11. Better data for better decisions

    Sophie Cooper, senior scientific adviser at NICE, explains the importance of the recently published EQ-5D-5L value set and how it has the potential to help us decide if new treatments offer good value for money for the NHS.

  12. PredictSURE IBD and IBDX to guide treatment of Crohn's disease (HTG610)

    Evidence-based recommendations on PredictSURE IBD and IBDX for guiding treatment of Crohn’s disease.

  13. Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy for treating morbid obesity (HTG423)

    Evidence-based recommendations on single-anastomosis duodeno-ileal bypass with sleeve gastrectomy for treating morbid obesity. This involves reducing the size of the stomach and small intestine to reduce the amount of food absorbed.

  14. Ultrasound‑enhanced, catheter‑directed thrombolysis for pulmonary embolism (HTG376)

    Evidence-based recommendations on ultrasound enhanced catheter-directed thrombolysis for pulmonary embolism. This involves using ultrasound waves and a drug to break up the clot.

  15. Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders (TA748)

    Evidence-based recommendations on mexiletine (Namuscla) for treating the symptoms of myotonia in adults with non-dystrophic myotonic disorders.